Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals ... of the author and do not necessarily reflect those of Nasdaq, Inc. With headquarters in the heart of Chicago's financial district ...

In the pre-market hours, Regeneron's stock is trading at $547.72, down 0.28 percent on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not ...

Regeneron Pharmaceuticals (NASDAQ:REGN) said on Thursday that the U.S. FDA will be reviewing the supplemental biologics ...

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on ...